Krishna Institute of Medical Sciences Limited entered a lease agreement on 21 December 2025 to set up a 300-bed super specialty hospital in Chennai, with an expected investment of ₹300 crore, funded through bank loans and internal accruals, as per exchange disclosures.
Source: Krishna Institute of Medical Sciences Limited Press Release (NSE Exchange Filings) | Published on Dec 21, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Krishna Institute of Medical Sciences Limited (NSE Exchange Filings), the company has entered into a Leave and License Agreement with Andhra Mahila Sabha for taking land on lease in Chennai, Tamil Nadu. The disclosure was made to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The leased land measures approximately 1.168 acres, equivalent to 21.19 grounds, and is located at Dr. Durgabai Deshmukh Road, Raja Annamalai Puram, Chennai. The land has been taken on a long-term lease for the purpose of setting up a super specialty hospital facility.
The filing records that the proposed hospital will have an approximate capacity of 300 beds.
Also read: KNR Constructions Exits Four Road Projects in ₹1,543 Cr Deal
The proposed hospital has about 300 beds.
City: Chennai, Tamil Nadu; Address: Raja Annamalai Puram
Dimensions of the land: 1.168 acres
Investment planned: ₹300 crore
Ways to pay for things: bank loans and private accruals
Within 36 months is the time frame for adding capacity.
Date of the agreement: December 21, 2025
The agreement has been executed with Andhra Mahila Sabha, a third-party lessor. The company disclosed that the lease arrangement relates only to land and does not involve any transfer of ownership.
The filing confirms that the disclosure complies with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024. The same intimation has been uploaded on the company’s website under Regulation 30 disclosures.
As per the annexure attached to the exchange filing, the company, along with its subsidiaries, reported an overall operational bed capacity of more than 8,800 beds as of 30 September 2025.
As of September 30, 2025, the capacity utilisation during the first six months of fiscal year 2026 (FY26) was approximately 51.0%. This information is included within the Department of Finance's mandatory disclosure requirements and is presented without analytical commentary.
The Company has stated that it expects to invest approximately ₹300 Crores into the Chennai super specialty hospital project, which will cover lease rental commitments and the cost of building a new hospital structure along with purchasing various types of medical equipment.
According to the company's submission, funds to cover this investment will come from both lending institutions as well as by the company's own generated revenue.
No other funding instruments have been disclosed in the intimation.
Particulars | Details |
Existing bed capacity | 8,800+ beds |
Capacity utilisation (H1 FY26) | ~51.0% |
Proposed additional capacity | ~300 beds |
Timeline for addition | Within 36 months |
Estimated investment | ₹300 crore |
As per the market data snapshot on 24 December 2025 at 15:30 PM IST, the Krishna Institute of Medical Sciences’ share price stood at ₹629.00 on the NSE. The stock showed a change of ₹-11.80 (-1.84%) compared with the previous close.
Also Read: Vikran Engineering Bags ₹459.2cr NTPC Renewable EPC Order
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading